A B S T R A C T Peripheral blood mononuclear cells from 46 systemic lupus erythematosus (SLE) patients showed reduced ability to proliferate in vitro in response to the soluble antigen, tetanus toxoid, as compared with 96 normal controls. Special studies of27 untreated SLE patients also revealed significantly decreased blastogenic responses to tetanus toxoid. In both the total and untreated SLE populations, decreased mean tetanus antibody titers also were found as compared with the control population. However, the reduction in antibody titer and blastogenic response was not strictly parallel.
INTRODUCTION
Considerable current interest has been focused on the possibility T-cell alterations in patients with systemic lupus erythematosus (SLE)1 playing a significant role in the immunological alterations characteristic Dr. Lahita is a Clinical Scholar at The Rockefeller University. Dr. Chiorazzi is a recipient of a fellowship from the Arthritis Foundation.
Received for publication 22 November 1978 and in revised form 10 January 1979. 'Abbreviations used in this paper: EN, neuraminidasetreated sheep erythrocytes; Fr II, fraction II; M0, monocytes; PBMC, peripheral blood mononuclear cells; PHA, phytohemagglutinin; SLE, systemic lupus erythematosus; TT, tetanus toxoid. of this disease. Although many groups have studied this question and some evidence for this possibility has been obtained (1) (2) (3) (4) (5) , the literature to date is confusing. For example, two reports on the blastogenic response of T cells to antigen stimulation have drawn completely opposite conclusions (6, 7) , and it was recently reported that impaired cellular immune function was the result solely of steroid therapy (7) . Contributing factors to the conflicting reports include differences in patient selection, effects of drug therapy on cellular immune function, and technical variability of in vitro assays. Recent interest in these questions has intensified in view of recent reports suggesting a decrease of suppressor cells in SLE patients (8, 9) .
Previous studies from our laboratory had indicated T-cell defects in studying the response of T lymphocytes in mixed leukocytic culture reactions (10) and in the release ofmigration inhibiting factor to measles antigen (11) in SLE patients. The present studies were undertaken to define more completely the T-cell response to antigen in these patients, employing the tetanus toxoid system that has long been studied in this laboratory for other purposes. In addition, it was planned to examine antibody responses at the same time and attempt to relate these to T-cell function.
METHODS Cell isolations. Peripheral blood mononuclear cells (PBMC)
were isolated on Ficoll-Hypaque (Ficoll, Pharmacia Fine Chemicals, Piscataway, N. J., Hypaque, Winthrop Laboratories, New York) density gradients followed by four washes in phosphate-buffered saline. T cells were isolated from PBMC on Ficoll-Hypaque gradients according to their capacity to form rosettes with neuraminidase-treated sheep erythrocytes (EN) and were quantified by EN-rosetting as described (12) .
Isolated T cells were always >90% pure and non-T-cell fractions were typically 20-30% B cells, 60-70% monocytes, and 1-10% T cells. Monocytes were isolated from PBMC by adherence onto plastic microtiter plates in RPMI 1640 (Microbiological Associates, Walkersville, Md.)-10% fetal calf serum. 0.05 ml PBMC/6-mm microtiter well were adhered for 90 min at 37°C in a 5% CO2-atmosphere, followed by two washes with phosphate-buffered saline (13 Miscellaneous. Hemagglutination of TT-coated human erythrocytes by plasma or serum was performed as described in Ling et al. (14) .
Fraction II (Fr II) was isolated by DEAE chromatography. Purified Fr II was spun at 40,000 rpm for 60 min, and the top 2 ml of supemate was removed. This fraction was monomeric Fr II. The remainder was aggregated by heating at 62°C for 20 min followed by spinning at 8,000 rpm for 30 min to remove large aggregates.
A Fig. 1 ). Anti-TT titers were determined as in Table II and antibody titer was poor in both the SLE and normal groups but was stronger in the SLE population than in the normals (r = 0.42 for SLE; r = 0.15 for normal). Perhaps most striking in the SLE group was the complete absence of antibody in 16 of the 44 patients. This was found in only 2 of 88 controls. The zero antibody SLE group included both untreated and treated patients. Only one of these showed a blastogenic response above 10,000 cpm. Low blastogenic responses were also observed in many of the patients with very significant antibody levels. Failure of immunization to restore SLE blastogenic response to TT in most cases. Previous studies of the effect of immunization on tetanus antibody titers have shown the response usually fell 10 yr after immunization (15) . Careful histories of the control and SLE individuals indicated that dissimilar immunization histories did not appear to account for differences observed. In addition, a limited immunization program was initiated in low-responder volunteers from each group. Individuals were immunized once with 0.5 ml of TT fluid subcutaneously and then bled once a week for 1 mo after immunization. Aggregated or monomeric Fr II was added to PBMC of a normal responder to TT to mimic the effect of immune complexes on T-cell function. Over a concentration range offrom 1 to 200 ,ug/ml, the response ofnormal PBMC in the presence of aggregated or monomeric Fr II was identical.
Recently, it was reported that glass wool-adherent lymphocytes secreted prostaglandins that suppressed the blastogenic response to PHA in normal individuals and in patients with Hodgkin's disease (20) . Indomethacin, an irreversible inhibitor of prostaglandin synthetase, was added to cultures of TT and PBMC from four SLE patients. Concentrations up to 10 ,ug/ml failed to significantly enhance SLE blastogenic response to TT. Clear evidence was gained in this study for reduced levels of antibody to TT in the SLE group. This was especially striking in certain patients; 36% had no detectable antibody, as compared with only 2% in the control group. Too few observations were made in the present study to determine the direct antibody response to TT, a project difficult to carry out in untreated patients; the few patients studied showed an antibody response to TT. It could be that the SLE cases lose their antibody titer more readily than normals and that this is the explanation ofthe low levels encountered. Previous studies of SLE antibody response to immunization have been conflicting. SLE patients showed normal responses to immunization with influenza (22) (23) (24) , TT (1), Brucella and Rickettsia (25) , and had normal levels of antibodies to AB blood group antigens and Proteus OX-2 (26) . In other studies, decreased SLE antibody responses were found upon immunization with influenza (27) and Brucella (28) . SLE patients showed decreased levels ofantibodies to streptolysin 0 (26) and of natural antibodies to Escherichia coli and Shigella antigens (28) . On the other hand, elevated SLE antibody responses were found against penicillin (29) , blood group antigens (30) , and a variety of viral antigens (31) (32) (33) (34) (35) (37) . However, other studies have indicated that the helper T cell and the antigen-reactive, proliferating T cell might not be the same cell (39) (40) (41) .
Impaired Immune Function in Systemic Lupus
Because it is known that in addition to T The mechanisms of decreased T-cell proliferation in response to TT remain unknown. Antilymphocyte antibodies from SLE patients have been reported to inhibit antigen and mitogen reactivity of autologous and homologous lymphocytes (10, 42) . However, serum samples from the vast majority of SLE patients failed to inhibit normal blastogenic responses to TT. It is possible that some SLE patients produce high affinity antilymphocyte antibodies that fix in vivo to antigen-responsive T cells and eliminate them from the circulation despite inability to detect these antibodies in vitro. Despite some reduction in lymphocyte count, the percentage of T cells was normal for most SLE patients studied. T-cell unresponsiveness to antigen might be caused by a failure of soluble factor production or an inability to recognize antigen. Immune complexes did not appear to account for decreased reactivity. Aggregated Fr II failed to inhibit a normal proliferative response to TT. Addition of SLE sera, known to contain immune complexes by Raji radioimmunoassay and analytical ultracentrifugation, did not inhibit the proliferative response of normal PBMC to TT. Just how the defect in T-cell response to TT relates to other T-cell abnormalities, such as a decrease in suppressor cells, is not clear. The T-cell populations involved in these two systems are entirely different (43) . It seems possible that a general T-cell defect is present in these patients. However, assays of allogeneic helper factor generation, another test of T-cell function (44) , was found to be normal. Further studies are required to determine these relationships.
